Recently, Hursting and Colleagues reported that treatment with the mTOR inhibitor everolimus abolishes the tumorigenic effects associated with obesity, improves calorie restriction-mediated anticancer activity, and blocks mammary tumor development and mTOR activation (121). This evidence concerns the gene MTOR and breast cancer.